Literature DB >> 10394613

The direct costs of insomnia in France.

D Leger1, E Levy, M Paillard.   

Abstract

Several reports indicate that use of hypnotics is significantly higher in France relative to other European countries, but few reports exist concerning the cost of this high consumption of psychotropic medications. The purpose of the present study was to estimate the direct costs that may be attributed to insomnia in France. Data were derived from previously published surveys in this field. It includes the cost of sleep medications and of substances used to promote sleep, outpatient visits to physicians or to other health professionals and sleep recordings and treatment by sleep specialists. The final estimate of the total direct cost of insomnia in France in 1995 was FF 10,232,992,500 ($2,067,271,100). Public authorities have to understand that an increase in the direct costs of insomnia may be balanced by the reduction of the daytime consequences of insomnia and then by the reduction of the indirect costs of insomnia.

Entities:  

Mesh:

Year:  1999        PMID: 10394613

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  11 in total

1.  Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation.

Authors:  Evelyn Mai; Daniel J Buysse
Journal:  Sleep Med Clin       Date:  2008

2.  Stress-related sleep disturbance and polysomnographic response to caffeine.

Authors:  Christopher L Drake; Catherine Jefferson; Timothy Roehrs; Thomas Roth
Journal:  Sleep Med       Date:  2006-09-22       Impact factor: 3.492

Review 3.  Insomnia in Elderly Patients: Recommendations for Pharmacological Management.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

Review 4.  Economic implications of sleep disorders.

Authors:  Tracy L Skaer; David A Sclar
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers.

Authors:  Meagan Daley; Charles M Morin; Mélanie LeBlanc; Jean-Pierre Grégoire; Josée Savard
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

6.  A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial.

Authors:  Catherine Cornu; Laurent Remontet; Florence Noel-Baron; Alain Nicolas; Nathalie Feugier-Favier; Pascal Roy; Bruno Claustrat; Mitra Saadatian-Elahi; Behrouz Kassaï
Journal:  BMC Complement Altern Med       Date:  2010-06-22       Impact factor: 3.659

Review 7.  The prevalence, cost implications, and management of sleep disorders: an overview.

Authors:  Jamil L Hossain; Colin M Shapiro
Journal:  Sleep Breath       Date:  2002-06       Impact factor: 2.816

8.  Workplace bullying and sleep disturbances: findings from a large scale cross-sectional survey in the French working population.

Authors:  Isabelle Niedhammer; Simone David; Stephanie Degioanni; Anne Drummond; Pierre Philip; D Acquarone; F Aicardi; P André-Mazeaud; M Arsento; R Astier; H Baille; F Bajon-Thery; E Barre; C Basire; J L Battu; S Baudry; C Beatini; N Beaud'huin; C Becker; D Bellezza; C Beque; O Bernstein; C Beyssier; F Blanc-Cascio; N Blanchet; C Blondel; R Boisselot; G Bordes-Dupuy; N Borrelly; D Bouhnik; M F Boulanger; J Boulard; P Borreau; D Bourret; A M Boustière; C Breton; G Bugeon; M Buono-Michel; J F Canonne; D Capella; M Cavin-Rey; C Cervoni; D Charreton; D Charrier; M A Chauvin; B Chazal; C Cougnot; G Cuvelier; G Dalivoust; R Daumas; A Debaille; L De Bretteville; G Delaforge; A Delchambre; L Domeny; Y Donati; J Ducord-Chapelet; C Duran; D Durand-Bruguerolle; D Fabre; A Faivre; R Falleri; G Ferrando; J Ferrari-Galano; M Flutet; J P Fouché; F Fournier; E Freyder; M Galy; A Garcia; G Gazazian; C Gérard; F Girard; M Giuge; C Goyer; C Gravier; A Guyomard; M C Hacquin; E Halimi; T Ibagnes; P Icart; M C Jacquin; B Jaubert; J P Joret; J P Julien; M Kacel; E Kesmedjian; P Lacroix; M Lafon-Borelli; S Lallai; J Laudicina; X Leclercq; S Ledieu; J Leroy; L Leroyer; F Loesche; D Londi; J M Longueville; M C Lotte; S Louvain; M Lozé; M Maculet-Simon; G Magallon; V Marcelot; M C Mareel; P Martin; A M Masse; M Méric; C Milliet; R Mokhtari; A M Monville; B Muller; G Obadia; M Pelser; L Peres; E Perez; M Peyron; F Peyronnin; S Postel; P Presseq; E Pyronnet; C Quinsat; H Raulot-Lapointe; P Rigaud; F Robert; O Robert; K Roger; A Roussel; J P Roux; D Rubini-Remigy; N Sabate; C Saccomano-Pertus; B Salengro; P Salengro-Trouillez; E Samson; L Sendra-Gille; C Seyrig; G Stoll; N Tarpinian; M Tavernier; S Tempesta; H Terracol; F Torresani; M F Triglia; V Vandomme; F Vieillard; K Vilmot; N Vital
Journal:  Sleep       Date:  2009-09       Impact factor: 5.849

9.  Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.

Authors:  Sonya J Snedecor; Marc F Botteman; Chris Bojke; Kendyl Schaefer; Nadine Barry; A Simon Pickard
Journal:  Sleep       Date:  2009-06       Impact factor: 5.849

10.  The size, burden and cost of disorders of the brain in the UK.

Authors:  Naomi A Fineberg; Peter M Haddad; Lewis Carpenter; Brenda Gannon; Rachel Sharpe; Allan H Young; Eileen Joyce; James Rowe; David Wellsted; David J Nutt; Barbara J Sahakian
Journal:  J Psychopharmacol       Date:  2013-07-24       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.